Roche's Cancer Injection Tecentriq SC Gets European Commission Approval
By Andrea Figueras
Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple cancer types.
The Swiss pharmaceutical company said Tuesday that it has been granted marketing authorisation for Tecentriq SC, which reduces treatment time by approximately 80% compared with standard IV infusion.
The subcutaneous injections take between four and eight minutes, while until now the treatment had been given directly into patients' veins by IV infusion, which takes approximately 30-60 minutes.
Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladder and breast cancer, Roche said.
The company is also working closely with several providers in Europe to include Tecentriq SC in cancer homecare initiatives where possible.
The injections can also be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home, depending on national regulations and health systems.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
January 16, 2024 01:34 ET (06:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?